Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/X_oW7F2pzb4/261409.php
Wednesday, 5 June 2013
Nivolumab Tested For Safety In Kidney Cancer
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center presented a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting. Metastatic renal cell carcinoma or kidney cancer is the seventh most common cancer, leading to approximately 116,000 deaths annually worldwide. In roughly one-quarter of those with mRCC, the cancer has already spread or metastasized at diagnosis...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment